Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q4 EPS by 131c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $79.90 -2.56%
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +4.8%
Financial Fact:
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD: -19.42M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q4 EPS of ($1.92), $1.31 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $240.73 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- After-Hours Stock Movers: FDX, CBRS, NKE
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
